However, a large number of independent case series exist that report successful use of rituximab, in patients with MG, particularly MuSK-Ab-positive MG (level IV evidence).40,41 In a prospective open-label study of 22 patients with refractory MG treated with rituximab, the median time to relapse was 17 months. This evidence concerns the gene MUSK and myasthenia gravis.